InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “GLP-1 Peptide Synthesis CDMO Market”-, By Synthesis Technology (Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), Group-Assisted Purification Peptide Synthesis (GAP-PS), Hybrid Technology, Recombinant DNA Technology), By Service Type (Analytical and Process Development, Large-Scale Production, Custom Peptide Synthesis, Peptide Modification, Purification Technology, Formulation Development, Regulatory Support, Packaging and Labeling, Pre-Formulation and Registration Batches), By Scale of Operation (Clinical-Scale Manufacturing, Commercial-Scale Manufacturing, Pilot-Scale Manufacturing), By End-User(Pharmaceutical Companies, Biotechnology Companies, Research Institutions, and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2034.”
Global GLP-1 Peptide Synthesis CDMO Market Size is predicted to grow at a 12.7 % CAGR during the forecast period for 2025-2034.
Check this Report Brochure : https://www.insightaceanalytic.com/request-sample/3105
A GLP-1 peptide synthesis CDMO (Contract Development and Manufacturing Organization) is a specialized third-party provider that offers comprehensive services for the development, synthesis, and GMP-compliant manufacturing of GLP-1 (Glucagon-Like Peptide-1) peptides. These synthetic compounds mimic the natural GLP-1 hormone. They are widely used in the treatment of type 2 diabetes and obesity due to their ability to stimulate insulin secretion and regulate blood glucose levels.
CDMOs serve as key partners for biopharmaceutical and biotechnology companies, offering expertise in solid-phase peptide synthesis (SPPS) or liquid-phase peptide synthesis (LPPS) to produce high-purity peptides. The synthesis process often involves modifications, such as incorporating fatty acid chains, to enhance half-life and requires precise control to ensure correct folding, bioactivity, stability, and regulatory compliance for GLP-1 analogues.
Pharmaceutical companies are increasingly outsourcing GLP-1 peptide synthesis to contract development and manufacturing organisations (CDMOs) due to the complexity, high capital investment, and specialised expertise required for peptide production. Advancements in solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) have significantly enhanced production efficiency, yield, and scalability.
The integration of AI and machine learning is also transforming peptide development, with companies like ImmunoPrecise Antibodies designing AI-optimized GLP-1 peptides that demonstrate superior receptor activation compared to semaglutide. Additionally, the expiration of patents for blockbuster GLP-1 drugs such as semaglutide is fueling demand for generic and biosimilar peptides, prompting CDMOs to scale up production of bioequivalent APIs using advanced purification techniques like HPLC and mass spectrometry. Smaller biotech firms, which often lack in-house peptide synthesis capabilities, are further driving CDMO growth by seeking flexible, small-scale production solutions for preclinical and clinical trial needs.
List of Prominent Players in the GLP-1 Peptide Synthesis CDMO Market:
- Bachem Holding AG
- CordenPharma
- PolyPeptide Group
- AmbioPharm
- CPC Scientific
- CSBio
- Creative Peptides
- Lonza
- Aurisco Pharmaceutical
- Hybio Pharmaceuticals
- Chinese Peptide Company
- Neuland Laboratories
- Divis Laboratories
- Supriya Lifescience
- Allsino Pharmaceutical Co. Ltd
Market Dynamics:
Drivers:
The global surge in type 2 diabetes and obesity has significantly increased the demand for GLP-1 drugs such as semaglutide and tirzepatide, which are widely used for glycemic control and weight management. Due to the complex and resource-intensive nature of peptide synthesis, pharmaceutical companies are increasingly turning to contract development and manufacturing organizations (CDMOs) to reduce production costs and access specialized expertise. CDMOs offer comprehensive solutions, spanning research and development through to commercial-scale manufacturing, making them attractive partners for both large pharmaceutical companies and smaller biotech firms.
Advances in solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and automation are further improving production efficiency and scalability. Additionally, the expiration of patents for blockbuster GLP-1 drugs, such as semaglutide, is accelerating the need for generics and biosimilars, prompting contract development and manufacturing organizations (CDMOs) to scale up the production of high-quality, bioequivalent peptides.
Challenges:
Peptide synthesis is highly capital- and resource-intensive, especially when scaled up for commercial production. The process involves the use of expensive raw materials and specialized reagents, which significantly drive-up manufacturing costs. Additionally, the synthesis of complex peptides like GLP-1 analogs often results in low process yields, particularly during the purification stage, further adding to the overall cost and complexity of production.
Regional Trends:
North America has the largest market share during the forecast period. GLP-1 peptide synthesis CDMO market due to a combination of advanced infrastructure, high therapeutic demand, and strong regulatory compliance. The U.S., in particular, is a global hub for pharmaceutical innovation and one of the largest consumers of GLP-1 receptor agonists. The region boasts a concentration of world-class CDMOs with GMP-compliant peptide synthesis capabilities. North America’s strict adherence to FDA regulations makes it a preferred outsourcing destination for both domestic and global pharmaceutical companies. However, Asia-Pacific is the fastest-growing region in the GLP-1 peptide synthesis CDMO market due to a mix of cost advantages, expanding healthcare infrastructure, and rising demand for diabetes and obesity treatments. Countries like China, India, and Japan are significantly increasing their investments in biopharmaceutical manufacturing, including peptide production, to meet both domestic and global demand.
Recent Developments:
- In Aug 2024, PolyPeptide, has teamed up to work on creating a GLP-1 agonist using a more environmentally friendly production process. The initiative will operate for the next 12 months after receiving a 1 million SEK prize from Sweden’s innovation agency, Vinnova. GLP-1 receptor agonist medicines are in high demand worldwide for treating diabetes and obesity. The production of peptides typically involves a high process mass intensity and the extensive use of dangerous solvents like N, N-dimethylformamide (DMF).
- In Sept2023, CordenPharma was pleased to announce the opening of expanded commercial peptide production capacity at CordenPharma Colorado, the world’s biggest solid-phase peptide synthesis (SPPS) manufacturing plant, with recently renovated facilities. Beginning capital investments in early 2023, CordenPharma has successfully finished many facilities upgrades and modernizations that have improved the productivity and efficiency of SPPS peptide production. This has given the company more capacity to serve both present and future clients across a growing base of pharmaceutical innovators.
Segmentation of GLP-1 Peptide Synthesis CDMO Market.
Global GLP-1 Peptide Synthesis CDMO Market – By Synthesis Technology
- Solid-Phase Peptide Synthesis (SPPS)
- Liquid-Phase Peptide Synthesis (LPPS)
- Group-Assisted Purification Peptide Synthesis (GAP-PS)
- Hybrid Technology
- Recombinant DNA Technology
Global GLP-1 Peptide Synthesis CDMO Market – By Service Type
- Analytical and Process Development
- Large-Scale Production
- Custom Peptide Synthesis
- Peptide Modification
- Purification Technology
- Formulation Development
- Regulatory Support
- Packaging and Labeling
- Pre-Formulation and Registration Batches
Global GLP-1 Peptide Synthesis CDMO Market – By Scale of Operation
- Clinical-Scale Manufacturing
- Commercial-Scale Manufacturing
- Pilot-Scale Manufacturing
Global GLP-1 Peptide Synthesis CDMO Market – By End-User
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutions
Global GLP-1 Peptide Synthesis CDMO Market – By Region
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
